Clinical Trial Update: Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer

View source ↗

Summary

Ongoing recruitment for a study evaluating immune responses to anti-HER2 therapies in patients with HER2-positive breast cancer across stages I through IV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Mayo Clinic | Conditions: Breast Adenocarcinoma, HER2-Positive Breast Carcinoma | Status: RECRUITING